Literature DB >> 17005812

Ciprofloxacin-resistant gram-negative bacilli in the fecal microflora of children.

Xuan Qin1, Yasmin Razia, James R Johnson, Jennifer R Stapp, Daniel R Boster, Treva Tsosie, Donna L Smith, Christopher R Braden, Kathryn Gay, Frederick J Angulo, Phillip I Tarr.   

Abstract

The extent to which antibiotic-resistant bacteria are excreted by humans who have not been exposed to antibiotics is not known. Children, who rarely receive fluoroquinolones, provide opportunities to assess the frequency of fecal excretion by fluoroquinolone-naïve hosts of fluoroquinolone-resistant gram-negative bacilli. Fresh nondiarrheal stools from children were processed by screening them on agar containing ciprofloxacin to recover ciprofloxacin-resistant gram-negative bacilli. Resistant isolates were identified, and ciprofloxacin MICs were determined. Resistant Escherichia coli isolates were also analyzed for urovirulence-associated loci. Thirteen (2.9%) of 455 stools yielded ciprofloxacin-resistant E. coli (seven children), Stenotrophomonas maltophilia (four children), and Achromobacter xylosoxidans and Enterobacter aerogenes (one child each). Neither the subjects themselves nor members of their households used fluoroquinolones in the 4 weeks preceding collection. Six of the seven resistant E. coli isolates belonged to phylogenetic groups B2 and D, in which extraintestinal pathogenic E. coli bacteria are frequently found. All resistant E. coli isolates contained at least three putative E. coli virulence loci. Most ciprofloxacin-resistant bacteria were resistant to additional antibiotics. Potentially pathogenic bacteria that are resistant to therapeutically important antimicrobial agents are excreted by some humans, despite these persons' lack of exposure to the particular drugs. The sources of these resistant organisms are unknown. This underrecognized reservoir of drug-resistant potential pathogens poses public health challenges.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17005812      PMCID: PMC1610095          DOI: 10.1128/AAC.00548-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

1.  Tetracycline resistance in Escherichia coli and persistence in the infantile colonic microbiota.

Authors:  Nahid Karami; Forough Nowrouzian; Ingegerd Adlerberth; Agnes E Wold
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

2.  Human diseases caused by foodborne pathogens of animal origin.

Authors:  Morton N Swartz
Journal:  Clin Infect Dis       Date:  2002-06-01       Impact factor: 9.079

3.  Extended virulence genotypes of Escherichia coli strains from patients with urosepsis in relation to phylogeny and host compromise.

Authors:  J R Johnson; A L Stell
Journal:  J Infect Dis       Date:  2000-01       Impact factor: 5.226

4.  Widespread distribution of urinary tract infections caused by a multidrug-resistant Escherichia coli clonal group.

Authors:  A R Manges; J R Johnson; B Foxman; T T O'Bryan; K E Fullerton; L W Riley
Journal:  N Engl J Med       Date:  2001-10-04       Impact factor: 91.245

5.  Animal antibiotic use has an early but important impact on the emergence of antibiotic resistance in human commensal bacteria.

Authors:  David L Smith; Anthony D Harris; Judith A Johnson; Ellen K Silbergeld; J Glenn Morris
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-23       Impact factor: 11.205

Review 6.  Safety profile of quinolone antibiotics in the pediatric population.

Authors:  Richard Grady
Journal:  Pediatr Infect Dis J       Date:  2003-12       Impact factor: 2.129

Review 7.  Pathophysiology and management of pulmonary infections in cystic fibrosis.

Authors:  Ronald L Gibson; Jane L Burns; Bonnie W Ramsey
Journal:  Am J Respir Crit Care Med       Date:  2003-10-15       Impact factor: 21.405

8.  Phylogenetic background and virulence profiles of fluoroquinolone-resistant clinical Escherichia coli isolates from the Netherlands.

Authors:  James R Johnson; Cindy van der Schee; Michael A Kuskowski; Wil Goessens; Alex van Belkum
Journal:  J Infect Dis       Date:  2002-11-22       Impact factor: 5.226

9.  An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project.

Authors:  G Kahlmeter
Journal:  J Antimicrob Chemother       Date:  2003-01       Impact factor: 5.790

10.  Isolation and molecular characterization of nalidixic acid-resistant extraintestinal pathogenic Escherichia coli from retail chicken products.

Authors:  James R Johnson; Andrew C Murray; Abby Gajewski; Maureen Sullivan; Paula Snippes; Michael A Kuskowski; Kirk E Smith
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

View more
  12 in total

1.  Intestinal inflammatory biomarkers and outcome in pediatric Clostridium difficile infections.

Authors:  Rana E El Feghaly; Jennifer L Stauber; Phillip I Tarr; David B Haslam
Journal:  J Pediatr       Date:  2013-09-04       Impact factor: 4.406

2.  Real-Time PCR Assay for Detection and Differentiation of Shiga Toxin-Producing Escherichia coli from Clinical Samples.

Authors:  Xuan Qin; Eileen J Klein; Emmanouil Galanakis; Anita A Thomas; Jennifer R Stapp; Shannon Rich; Anne Marie Buccat; Phillip I Tarr
Journal:  J Clin Microbiol       Date:  2015-04-29       Impact factor: 5.948

3.  Gut Colonization of Healthy Children and Their Mothers With Pathogenic Ciprofloxacin-Resistant Escherichia coli.

Authors:  Emily A Gurnee; I Malick Ndao; James R Johnson; Brian D Johnston; Mark D Gonzalez; Carey-Ann D Burnham; Carla M Hall-Moore; Jessica E McGhee; Alexander Mellmann; Barbara B Warner; Phillip I Tarr
Journal:  J Infect Dis       Date:  2015-05-12       Impact factor: 5.226

Review 4.  Resistance surveillance studies: a multifaceted problem--the fluoroquinolone example.

Authors:  A Dalhoff
Journal:  Infection       Date:  2012-03-30       Impact factor: 3.553

5.  Virulence factors in urinary Escherichia coli strains: phylogenetic background and quinolone and fluoroquinolone resistance.

Authors:  Gabriella Piatti; Alessandro Mannini; Maria Balistreri; Anna Maria Schito
Journal:  J Clin Microbiol       Date:  2007-12-05       Impact factor: 5.948

6.  Functional metagenomic investigations of the human intestinal microbiota.

Authors:  Aimee M Moore; Christian Munck; Morten O A Sommer; Gautam Dantas
Journal:  Front Microbiol       Date:  2011-10-17       Impact factor: 5.640

Review 7.  Antibiotics and bacterial resistance in the 21st century.

Authors:  Richard J Fair; Yitzhak Tor
Journal:  Perspect Medicin Chem       Date:  2014-08-28

8.  Global fluoroquinolone resistance epidemiology and implictions for clinical use.

Authors:  Axel Dalhoff
Journal:  Interdiscip Perspect Infect Dis       Date:  2012-10-14

9.  Increased fluoroquinolone resistance with time in Escherichia coli from >17,000 patients at a large county hospital as a function of culture site, age, sex, and location.

Authors:  Lauren Becnel Boyd; Robert L Atmar; Graham L Randall; Richard J Hamill; David Steffen; Lynn Zechiedrich
Journal:  BMC Infect Dis       Date:  2008-01-15       Impact factor: 3.090

10.  Pediatric fecal microbiota harbor diverse and novel antibiotic resistance genes.

Authors:  Aimée M Moore; Sanket Patel; Kevin J Forsberg; Bin Wang; Gayle Bentley; Yasmin Razia; Xuan Qin; Phillip I Tarr; Gautam Dantas
Journal:  PLoS One       Date:  2013-11-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.